| pubmed-article:17116133 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17116133 | lifeskim:mentions | umls-concept:C0010823 | lld:lifeskim |
| pubmed-article:17116133 | lifeskim:mentions | umls-concept:C0376387 | lld:lifeskim |
| pubmed-article:17116133 | lifeskim:mentions | umls-concept:C0022671 | lld:lifeskim |
| pubmed-article:17116133 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:17116133 | pubmed:dateCreated | 2006-11-22 | lld:pubmed |
| pubmed-article:17116133 | pubmed:abstractText | We have retrospectively analyzed the incidence of cytomegalovirus (CMV) infection in 250 consecutive renal allograft transplants performed in 244 recipients. The mean follow-up was 35.1+/-25.4 months. Immunosuppression was cyclosporine- or tacrolimus-based triple therapy. CMV infection prophylaxis with ganciclovir for 3 months post transplant was prescribed in CMV-seronegative recipients of allografts from seropositive donors (D+R-) and in all recipients treated with OKT3. CMV antigenemia was monitored by the pp65-antigen assay. Thirteen of 57 D+R- recipients (22.8%) developed CMV antigenemia. One recipient had a breakthrough of CMV antigenemia during ganciclovir prophylaxis; 12 D+R- recipients developed CMV antigenemia 147.5+/-173.8 days after transplantation. Four of 13 (30.7%) D+R- recipients had asymptomatic CMV infection, 8 (61.6%) had CMV infection with non-specific symptoms including fever, and 1 (7.7%) developed CMV pneumonia. Six of 13 (46.1%) D+R- patients had been treated with intensified immunosuppressive therapy before CMV infection. In the low-risk CMV groups (D+R+; D-R+; D-R-), 28 recipients (14.5%) developed CMV antigenemia 42.5+/-15.2 days post transplantation. Ten of the 28 (35.7%) recipients had asymptomatic CMV infection, 17 (60.7%) developed CMV infection with non-specific symptoms, and 1 (3.6%) developed CMV pneumonia. Twenty-one of 28 (75.0%) had intensified immunosuppressive therapy before CMV infection. In conclusion, ganciclovir prophylaxis diminished and delayed the onset of CMV infection but did not totally prevent it from occurring in D+R- renal transplant recipients. Clinicians should be vigilant to the possibility of CMV infection in both seronegative and seropositive recipients, especially after anti-rejection therapy. | lld:pubmed |
| pubmed-article:17116133 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17116133 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17116133 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17116133 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17116133 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17116133 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17116133 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17116133 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:17116133 | pubmed:issn | 1398-2273 | lld:pubmed |
| pubmed-article:17116133 | pubmed:author | pubmed-author:SpencerEE | lld:pubmed |
| pubmed-article:17116133 | pubmed:author | pubmed-author:MadsenMM | lld:pubmed |
| pubmed-article:17116133 | pubmed:author | pubmed-author:AndersenH KHK | lld:pubmed |
| pubmed-article:17116133 | pubmed:author | pubmed-author:CarstensJJ | lld:pubmed |
| pubmed-article:17116133 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17116133 | pubmed:volume | 8 | lld:pubmed |
| pubmed-article:17116133 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17116133 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17116133 | pubmed:pagination | 203-12 | lld:pubmed |
| pubmed-article:17116133 | pubmed:meshHeading | pubmed-meshheading:17116133... | lld:pubmed |
| pubmed-article:17116133 | pubmed:meshHeading | pubmed-meshheading:17116133... | lld:pubmed |
| pubmed-article:17116133 | pubmed:meshHeading | pubmed-meshheading:17116133... | lld:pubmed |
| pubmed-article:17116133 | pubmed:meshHeading | pubmed-meshheading:17116133... | lld:pubmed |
| pubmed-article:17116133 | pubmed:meshHeading | pubmed-meshheading:17116133... | lld:pubmed |
| pubmed-article:17116133 | pubmed:meshHeading | pubmed-meshheading:17116133... | lld:pubmed |
| pubmed-article:17116133 | pubmed:meshHeading | pubmed-meshheading:17116133... | lld:pubmed |
| pubmed-article:17116133 | pubmed:meshHeading | pubmed-meshheading:17116133... | lld:pubmed |
| pubmed-article:17116133 | pubmed:meshHeading | pubmed-meshheading:17116133... | lld:pubmed |
| pubmed-article:17116133 | pubmed:meshHeading | pubmed-meshheading:17116133... | lld:pubmed |
| pubmed-article:17116133 | pubmed:meshHeading | pubmed-meshheading:17116133... | lld:pubmed |
| pubmed-article:17116133 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:17116133 | pubmed:articleTitle | Cytomegalovirus infection in renal transplant recipients. | lld:pubmed |
| pubmed-article:17116133 | pubmed:affiliation | Department of Renal Medicine, Aarhus University Hospital, Skejby Sygehus, Aarhus, Denmark. jcar@farm.au.dk | lld:pubmed |
| pubmed-article:17116133 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17116133 | lld:pubmed |
